48
total announcements
RPGLIFE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 14 Oct 2026
Market Cap
₹4,642 Cr
P/E (TTM)
38.8
P/E (Forward)
29.8
EPS (TTM)
₹72.34
52W Low
₹1,733.00
52W High
₹3,127.80
Dividend Yield
0.84%
Beta
-0.13
Price / Book
7.7
Debt / Equity
3.3
Revenue (TTM)
₹734 Cr
Gross Margin
63.81%
Operating Margin
19.11%
RPG Life Sciences Limited
RPG Life Sciences Limited has received a certificate from MUFG Intime India Private Limited confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, regarding dematerialisation of securities.
RPG Life Sciences Limited
RPG Life Sciences Limited has published a newspaper advertisement regarding a special window for lodgment of transfer and dematerialization requests for physical securities sold or purchased prior to April 1, 2019.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about a Scheme of Amalgamation of Actis Generics Private Limited with RPG Active Pharma Limited, subject to necessary approvals.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.
RPG Life Sciences Limited
RPG Life Sciences Limited has completed the acquisition of Actis Generics Private Limited, making it a subsidiary of the company, effective September 24, 2026.
RPG Life Sciences Limited
RPG Life Sciences Limited has responded to a query from the National Stock Exchange regarding a significant increase in trading volume, stating that there is no unpublished event or information that may have a bearing on the price or volume of the company's shares.
RPG Life Sciences Limited
RPG Life Sciences Limited has seen a significant increase in trading volume, prompting the exchange to seek clarification from the company.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about the schedule of an Analyst/Institutional Investors meet, which will be participated by the company on September 22, 2026, at 10:00 A.M. IST.
RPG Life Sciences Limited
RPG Life Sciences Limited has completed the business transfer agreement with Raghava Life Sciences Private Limited for the acquisition of Active Pharmaceutical Ingredients (APIs) and intermediates businesses as a going concern.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed that its subsidiary, RPG Active Pharma Limited, has allotted securities to investors India Life Sciences Fund IV Domestic and Vistaject Fund for a total consideration of INR 243.33 crores, constituting 40% of RPG Active Pharma's equity share capital.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about the link of recording for the Analyst/Institutional call held on September 3, 2026. The details are available on the company's website.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about Investors meet details, including dial-in information and a link to the company's website for further details.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about Investor Presentation, which includes details of its subsidiary RPG Active Pharma (RPGAP) acquiring Actis Generics and Raghava Life Sciences to enhance its product portfolio and capacity.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about hosting an investors/analyst call on September 3, 2026, to discuss the company's strategic announcement.
RPG Life Sciences Limited
RPG Life Sciences Limited's wholly owned subsidiary, RPG Active Pharma Limited, has acquired the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences Private Limited for up to ₹135 crore. The acquisition strengthens RPG Active Pharma's integrated API play and adds approximately 300 KL of installed capacity in a state-of-the-art EU-GMP approved plant and a portfolio of 22 commercialized APIs plus 7 under development.
RPG Life Sciences Limited
RPG Life Sciences Limited's wholly owned subsidiary, RPG Active Pharma Limited, has entered into a Business Transfer Agreement with Raghava Life Sciences Private Limited to acquire its Active Pharmaceutical Ingredients (APIs) and intermediates businesses on a going concern basis through a slump sale.
RPG Life Sciences Limited
RPG Life Sciences Limited has announced the execution of a Business Transfer Agreement by its wholly owned subsidiary, RPG Active Pharma Limited, with Raghava Life Sciences Private Limited for the acquisition of Active Pharmaceutical Ingredients (APIs) and intermediates Businesses as a going concern, by way of slump sale.
RPG Life Sciences Limited
RPG Life Sciences Limited has cancelled its investor meet scheduled for September 2, 2026, due to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed the Exchange about a scheduled Analyst/Institutional Investors meet on September 2, 2026, at 10:00 A.M. IST, which will be participated by the Company. The meet will be held in Mumbai/Physical mode.
RPG Life Sciences Limited
RPG Life Sciences Limited has informed about the Schedule of Analyst/Institutional Investors Meet, which will be participated by the company. The details of the meet are as follows: Date: August 25, 2026, Time: 10.00 A.M. (IST), Venue: Antique Healthcare, Mumbai, Mode: Physical Group Meet, Nature of Meeting: Investor Conference.